2 Beaten-Down Stocks That Could Sink Even More in 2026 [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
10 stocks we like better than Sarepta Therapeutics › The market had no love for Sarepta Therapeutics (NASDAQ: SRPT) and Teladoc Health (NYSE: TDOC) last year, as both companies lagged broader equities and lost significant market value. This might make them attractive at current levels if there are good reasons to think they will bounce back. However, that's hardly the case. Sarepta Therapeutics and Teladoc Health both face significant challenges that might, once again, lead to poor performance in 2026. Here's why neither stock is worth investing in right now. Last year, Sarepta's shares declined by more than 80% after its most important product faced safety concerns. The biotech company develops medicines for rare diseases, especially Duchenne muscular dystrophy (DMD), a condition that progressively weakens and degrades patients' muscles. Sarepta's gene therapy treatment, Elevidys, is the only one of its therapies to target the underlying causes of DMD. However, last year, tw
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s DiseaseBusiness Wire
- Sarepta's Elevidys Data Underscore Long Term Duchenne Therapy Durability [Yahoo! Finance]Yahoo! Finance
- Is Sarepta Therapeutics (SRPT) Pricing Reflect A 82% Share Price Slump And DCF Upside? [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $20.00 price target on the stock.MarketBeat
SRPT
Earnings
- 11/3/25 - Beat
SRPT
Sec Filings
- 1/29/26 - Form 4
- 1/29/26 - Form 4
- 1/21/26 - Form SCHEDULE
- SRPT's page on the SEC website